SV2006002317A - Formulaciones de benzoxazoles substituidos ref. wyth0097-503 (am101641) (178701) - Google Patents

Formulaciones de benzoxazoles substituidos ref. wyth0097-503 (am101641) (178701)

Info

Publication number
SV2006002317A
SV2006002317A SV2005002317A SV2005002317A SV2006002317A SV 2006002317 A SV2006002317 A SV 2006002317A SV 2005002317 A SV2005002317 A SV 2005002317A SV 2005002317 A SV2005002317 A SV 2005002317A SV 2006002317 A SV2006002317 A SV 2006002317A
Authority
SV
El Salvador
Prior art keywords
formulations
wyth0097
benzoxazols
ref
substituted
Prior art date
Application number
SV2005002317A
Other languages
English (en)
Inventor
James A Provost
Trevor I Armstrong
Zerina B Shafi
Marc S Tesconi
Ku Mannching S
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2006002317A publication Critical patent/SV2006002317A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DOSIS SÓLIDAS DE FORMULACIONES QUE INCLUYEN OS LIGADOS ERB-SELECTIVOS QUE CONTIENE BENZOXASOL Y LOS PROCESOS PARA FABRICAR DICHAS FORMULACIONES, MÁS PARTICULARMENTE A LAS FORMULACIONES NUEVAS Y PROCESOS PARA LA FABRICACIÓN DE FORMULACIONES QUE CONTIENEN EL LIGADO ERB-SELECTIVO, ERB-041
SV2005002317A 2004-12-02 2005-11-30 Formulaciones de benzoxazoles substituidos ref. wyth0097-503 (am101641) (178701) SV2006002317A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63237504P 2004-12-02 2004-12-02

Publications (1)

Publication Number Publication Date
SV2006002317A true SV2006002317A (es) 2006-06-26

Family

ID=36565706

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002317A SV2006002317A (es) 2004-12-02 2005-11-30 Formulaciones de benzoxazoles substituidos ref. wyth0097-503 (am101641) (178701)

Country Status (22)

Country Link
US (1) US20060121110A1 (es)
EP (1) EP1850833A2 (es)
JP (1) JP2008521919A (es)
KR (1) KR20070089921A (es)
CN (1) CN101128188A (es)
AR (1) AR053653A1 (es)
AU (1) AU2005311823A1 (es)
BR (1) BRPI0518786A2 (es)
CA (1) CA2589033A1 (es)
CR (1) CR9144A (es)
GT (1) GT200500349A (es)
IL (1) IL183393A0 (es)
MX (1) MX2007006564A (es)
NI (1) NI200700139A (es)
NO (1) NO20072636L (es)
NZ (1) NZ555395A (es)
PE (1) PE20061083A1 (es)
RU (1) RU2007120253A (es)
SV (1) SV2006002317A (es)
TW (1) TW200626144A (es)
WO (1) WO2006060532A2 (es)
ZA (1) ZA200705011B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600101A (es) * 2005-03-08 2006-11-09 Formas cristalinas de 2-(3-fluoro-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
CA2641116A1 (en) * 2006-02-14 2007-08-23 Wyeth Aqueous pharmaceutical formulations of er.beta. selective ligands
AR059742A1 (es) * 2006-03-06 2008-04-23 Wyeth Corp Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol
PE20080116A1 (es) * 2006-03-06 2008-02-25 Wyeth Corp Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
JP2009529061A (ja) * 2006-03-06 2009-08-13 ワイス 錠剤製剤およびプロセス
AR059741A1 (es) * 2006-03-06 2008-04-23 Wyeth Corp Formulaciones farmaceuticas liquidas y semisolidas y procedimientos
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
EP1345914A1 (en) * 2000-12-22 2003-09-24 AstraZeneca AB Therapeutic compounds
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2003220186A1 (en) * 2002-04-10 2003-10-27 Merck And Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant

Also Published As

Publication number Publication date
RU2007120253A (ru) 2009-01-10
WO2006060532A2 (en) 2006-06-08
ZA200705011B (en) 2010-01-27
NZ555395A (en) 2009-07-31
IL183393A0 (en) 2007-09-20
NI200700139A (es) 2008-05-09
JP2008521919A (ja) 2008-06-26
NO20072636L (no) 2007-08-13
US20060121110A1 (en) 2006-06-08
TW200626144A (en) 2006-08-01
AU2005311823A1 (en) 2006-06-08
MX2007006564A (es) 2007-06-19
PE20061083A1 (es) 2006-11-14
EP1850833A2 (en) 2007-11-07
KR20070089921A (ko) 2007-09-04
AR053653A1 (es) 2007-05-16
CA2589033A1 (en) 2006-06-08
BRPI0518786A2 (pt) 2008-12-09
GT200500349A (es) 2006-07-03
CR9144A (es) 2007-11-23
CN101128188A (zh) 2008-02-20
WO2006060532A3 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
SV2006002317A (es) Formulaciones de benzoxazoles substituidos ref. wyth0097-503 (am101641) (178701)
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CO6270311A2 (es) Derivados bis-(sulfonilamino) en terapia 066
UY31546A1 (es) Derivados bis-(sulfonilamino) en terapia 205
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
UY28482A1 (es) Nuevos compuestos
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
AR038045A1 (es) Agentes terapeuticos
ECSP034830A (es) Derivados sustituidos de la ciclohexano-1,4- diamina
UY26872A1 (es) Derivados de la 4- fenil piridina
UY27740A1 (es) Nuevos compuestos
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
UY31457A1 (es) Derivados acidos de cicloalquilamino
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
DOP2003000566A (es) Cicloalcanindoles con sustitución con fluor, composiciones que contienen estos compuestos y metodos de preparación para un medicamento
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
AR047922A1 (es) Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos
SV2004001548A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
PA8589801A1 (es) Aminoalcoxiindoles
AR052365A1 (es) Derivados antihelminticos de imidazol-tiazol
SV2007002357A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene ref. p-sv-79232/ug